Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Xponance Inc.

Xponance Inc. lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 1.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 138,977 shares of the medical research company’s stock after selling 2,186 shares during the period. Xponance Inc.’s holdings in Edwards Lifesciences were worth $10,597,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Moneta Group Investment Advisors LLC grew its holdings in Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock valued at $1,148,938,000 after buying an additional 15,384,593 shares during the last quarter. Norges Bank acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its holdings in Edwards Lifesciences by 440.0% during the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock valued at $243,173,000 after buying an additional 2,860,000 shares during the last quarter. AustralianSuper Pty Ltd acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Edwards Lifesciences by 655.9% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock valued at $173,502,000 after buying an additional 2,017,801 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.6 %

Shares of EW traded up $0.54 during trading hours on Friday, hitting $86.99. The stock had a trading volume of 271,954 shares, compared to its average volume of 3,817,347. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The firm has a market cap of $52.36 billion, a P/E ratio of 37.59, a P/E/G ratio of 4.32 and a beta of 1.05. The company’s fifty day simple moving average is $90.14 and its 200 day simple moving average is $78.19. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the company posted $0.64 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Morgan Stanley increased their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Evercore ISI raised their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Monday. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a report on Wednesday, February 7th. Finally, Truist Financial raised their price objective on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 over the last three months. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.